FREMONT, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Seeking to expand the knowledge base surrounding spectral flow cytometry, Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has launched a global roadshow called Cytek Reveal. The roadshow will kick off in South San Francisco on October 5, 2023, and will include stops in San Diego, Boston, Toronto and Cambridge, United Kingdom. Each stop will feature four distinct educational presentations that demonstrate how spectral flow cytometry can be used across a range of applications for analysis and sorting. Highlighted topics will include the similarities and differences, along with backward compatibility, between spectral and conventional cytometry. Spectral technology enables flexibility and high-resolution power, spanning from low-color to complex assays.

Recognized as a pioneer in spectral flow cytometry, Cytek is the creator of the first commercialized fluorescence-based flow cytometry platform to achieve 40 colors – effectively shifting the paradigm of what scientists thought was possible in flow cytometry. The company’s patented Full Spectrum Profiling™ (FSP™) technology empowers scientists, allowing them to go even further with their research – all with greater ease and shorter time to results compared to conventional flow cytometry. While the platform supports generation of high-resolution multiparametric data, Cytek’s FSP™ technology has proven to be useful across all flow cytometry applications.

The Cytek Reveal Roadshow will provide participants with an insider’s look into the breakthroughs that are possible using FSP™ technology. They will also learn about Cytek’s extensive suite of solutions for the single cell analysis market that streamline workflows, accelerate discoveries and maximize efficiency – including the Cytek^® Aurora CS system.

Sessions will be led by Dr. Maria Jaimes, Cytek’s vice president of scientific commercialization. Dr. Jaimes was part of the original team credited for developing and commercializing Cytek’s Aurora full spectrum cytometer and is a subject matter expert on multicolor flow cytometry.

“At Cytek, we’re committed to developing the tools that will advance the next generation of cell analysis – and becoming the partner of choice throughout the life sciences community,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “We take the word ‘partner’ very seriously, and constantly adapt our offerings to meet the needs of users. Our entire lineup is user-friendly and intuitive, allowing scientists at all levels to advance their research. We invite you to attend one of our roadshows and join us in the spectral revolution.”

Cytek solutions are well established globally, with over 1,300 peer-reviewed publications referencing the use of Cytek solutions in research ranging from immuno-oncology to infectious diseases and immunology. Backed by its hands-on, exceptional technical applications support teams, Cytek products are used at many of the world’s most renowned pharmaceutical companies, CRO firms, and academic research institutions.

“The Cytek perspective centers on technology as an enabler of scientific progress,” Dr. Jiang continued. “We are dedicated to crafting tools that empower scientists, and seek to foster accessibility and ease of use without compromising capabilities. By simplifying complex technologies, we allow researchers to channel their energy into what they do best – exploration and discovery.”

For more information and details on the Cytek Reveal Roadshow, please visit www.cytekbio.com/reveal or www.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer and imaging products under the Amnis^® and Guava^® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s product development goals and business strategies. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to global economic and market conditions; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek’s ability to maintain, protect and enhance its intellectual property; and Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2023 and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
This email address is being protected from spambots. You need JavaScript enabled to view it.